我国糖尿病与抑郁症"狼狈为奸"率高达10.8%

2016-09-20 佚名 生物谷

最近几天,男明星乔任梁因为严重的抑郁症而自杀身亡的消息,成为讨论热点。其实,相对于健康人,糖尿病患者更容易有抑郁状况。 流行病学数据表明,至少有三分之一的糖尿病患者会出现相关抑郁障碍,而抑郁症患者发生糖尿病的风险会增加37%。近日,第52届欧洲糖尿病研究协会(EASD)年会上公布的一项全球研究数据显示,中国2型糖尿病患者抑郁症发生率为10.8%。 共病导致临床结局变差 同时患有糖尿病和抑

最近几天,男明星乔任梁因为严重的抑郁症而自杀身亡的消息,成为讨论热点。其实,相对于健康人,糖尿病患者更容易有抑郁状况。

流行病学数据表明,至少有三分之一的糖尿病患者会出现相关抑郁障碍,而抑郁症患者发生糖尿病的风险会增加37%。近日,第52届欧洲糖尿病研究协会(EASD)年会上公布的一项全球研究数据显示,中国2型糖尿病患者抑郁症发生率为10.8%。

共病导致临床结局变差

同时患有糖尿病和抑郁症这两种疾病的患者出现疾病相关并发症的可能性,比只患其中一种疾病的患者高出2倍。因为另一种疾病的存在,导致两种疾病的预后都变得更差,包括疾病的严重程度,治疗抵抗率和死亡率增加,个体和社会的治疗花费明显上升,生活质量和糖尿病自我管理能力下降,并发症发生率提高,以及预期寿命减少。

抑郁症诊断率偏低

虽可使用筛查工具有效识别出抑郁患者,但糖尿病患者中抑郁症的诊断率仍偏低,相当多的抑郁症仍未得到诊治。

在1型或2型成人糖尿病患者中,有1/4的患者会出现明显的抑郁症状,但仅10%~15%的患者能得到正式诊断。目前国内在临床诊断方面,最常用ICD-10诊断标准。ICD-10要求抑郁发作诊断必须具备至少2项核心症状及2项以上附加症状。

核心症状包括:

(1)情绪低落;

(2)乐趣缺乏;

(3)精力不足。

附加症状包括:

(1)集中注意和主动注意的能力降低;

(2)自我评价和自信降低;

(3)自罪观念和无价值感;

(4)认为前途暗淡;

(5)自伤或自杀的观念或行为;

(6)睡眠障碍;

(7)食欲下降。

核心症状和附加症状的符合条目越多,抑郁程度就越重。

此外,还应符合以下条件:

(1)症状持续至少2周;

(2)并非继发于酒精或药物滥用、药物治疗、内科疾病或居丧反应;

(3)能引起明显日常活动或社会职业功能损害。

当医生面对血糖控制不佳、治疗依从性差、常有疼痛和其他躯体不适主诉及医患关系不良的糖尿病患者时,即应高度怀疑抑郁症的可能。

糖尿病是最需要心理和行为管理的慢性疾病,因为抑郁症和糖尿病的共病现象具有普遍性,美国糖尿病学会(ADA)推荐在糖尿病患者中常规进行抑郁症筛查(尤其是那些依从性差的患者),符合抑郁症的患者应长期监测糖尿病症状和危险因素的进展情况,包括血糖、饮食、运动、吸烟和药物依从性。

三大治疗策略

糖尿病患者抑郁症治疗有三大策略,即糖尿病的自我管理教育、心理治疗和药物治疗。恰当的治疗手段既可改善抑郁症状,又能有助于控制血糖。

和糖尿病的自我管理一样,近期针对抑郁症的自我管理模式——基于评估的治疗,也证明比常规治疗更加可行和有效。心理治疗联合糖尿病教育的方法,对抑郁症状和血糖控制均有中到高度的改善效果。之前研究表明,共病抑郁症和糖尿病的患者接受抗抑郁治疗是有效的。(生物谷 Bioon.com)

资料参考:

http://www.medscape.com/viewarticle/868814

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=134101, encodeId=171013410101, content=内容不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Sat Sep 24 08:17:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=134103, encodeId=113013410324, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Sat Sep 24 08:17:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132440, encodeId=2afd132440b2, content=能不能探讨一下共病机制,共同通路,否则还是新瓶装旧酒,老生常谈,能怎样呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Wed Sep 21 18:42:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131974, encodeId=c7ab1319e491, content=以前忽略了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170206/IMG589879E392F941842.jpg, createdBy=f4d469996, createdName=wangyunyb, createdTime=Wed Sep 21 07:28:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131841, encodeId=0f531318412e, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 20 22:52:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131842, encodeId=67a113184259, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 20 22:52:00 CST 2016, time=2016-09-20, status=1, ipAttribution=)]
    2016-09-24 187清风

    内容不错

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=134101, encodeId=171013410101, content=内容不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Sat Sep 24 08:17:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=134103, encodeId=113013410324, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Sat Sep 24 08:17:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132440, encodeId=2afd132440b2, content=能不能探讨一下共病机制,共同通路,否则还是新瓶装旧酒,老生常谈,能怎样呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Wed Sep 21 18:42:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131974, encodeId=c7ab1319e491, content=以前忽略了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170206/IMG589879E392F941842.jpg, createdBy=f4d469996, createdName=wangyunyb, createdTime=Wed Sep 21 07:28:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131841, encodeId=0f531318412e, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 20 22:52:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131842, encodeId=67a113184259, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 20 22:52:00 CST 2016, time=2016-09-20, status=1, ipAttribution=)]
    2016-09-24 187清风

    继续关注

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=134101, encodeId=171013410101, content=内容不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Sat Sep 24 08:17:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=134103, encodeId=113013410324, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Sat Sep 24 08:17:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132440, encodeId=2afd132440b2, content=能不能探讨一下共病机制,共同通路,否则还是新瓶装旧酒,老生常谈,能怎样呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Wed Sep 21 18:42:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131974, encodeId=c7ab1319e491, content=以前忽略了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170206/IMG589879E392F941842.jpg, createdBy=f4d469996, createdName=wangyunyb, createdTime=Wed Sep 21 07:28:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131841, encodeId=0f531318412e, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 20 22:52:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131842, encodeId=67a113184259, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 20 22:52:00 CST 2016, time=2016-09-20, status=1, ipAttribution=)]
    2016-09-21 lyh994

    能不能探讨一下共病机制,共同通路,否则还是新瓶装旧酒,老生常谈,能怎样呢?

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=134101, encodeId=171013410101, content=内容不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Sat Sep 24 08:17:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=134103, encodeId=113013410324, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Sat Sep 24 08:17:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132440, encodeId=2afd132440b2, content=能不能探讨一下共病机制,共同通路,否则还是新瓶装旧酒,老生常谈,能怎样呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Wed Sep 21 18:42:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131974, encodeId=c7ab1319e491, content=以前忽略了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170206/IMG589879E392F941842.jpg, createdBy=f4d469996, createdName=wangyunyb, createdTime=Wed Sep 21 07:28:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131841, encodeId=0f531318412e, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 20 22:52:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131842, encodeId=67a113184259, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 20 22:52:00 CST 2016, time=2016-09-20, status=1, ipAttribution=)]
    2016-09-21 wangyunyb

    以前忽略了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=134101, encodeId=171013410101, content=内容不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Sat Sep 24 08:17:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=134103, encodeId=113013410324, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Sat Sep 24 08:17:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132440, encodeId=2afd132440b2, content=能不能探讨一下共病机制,共同通路,否则还是新瓶装旧酒,老生常谈,能怎样呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Wed Sep 21 18:42:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131974, encodeId=c7ab1319e491, content=以前忽略了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170206/IMG589879E392F941842.jpg, createdBy=f4d469996, createdName=wangyunyb, createdTime=Wed Sep 21 07:28:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131841, encodeId=0f531318412e, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 20 22:52:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131842, encodeId=67a113184259, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 20 22:52:00 CST 2016, time=2016-09-20, status=1, ipAttribution=)]
    2016-09-20 知难而进

    谢谢分享!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=134101, encodeId=171013410101, content=内容不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Sat Sep 24 08:17:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=134103, encodeId=113013410324, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb571956164, createdName=187清风, createdTime=Sat Sep 24 08:17:00 CST 2016, time=2016-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132440, encodeId=2afd132440b2, content=能不能探讨一下共病机制,共同通路,否则还是新瓶装旧酒,老生常谈,能怎样呢?, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Wed Sep 21 18:42:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131974, encodeId=c7ab1319e491, content=以前忽略了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170206/IMG589879E392F941842.jpg, createdBy=f4d469996, createdName=wangyunyb, createdTime=Wed Sep 21 07:28:00 CST 2016, time=2016-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131841, encodeId=0f531318412e, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 20 22:52:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131842, encodeId=67a113184259, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Tue Sep 20 22:52:00 CST 2016, time=2016-09-20, status=1, ipAttribution=)]
    2016-09-20 知难而进

    继续关注!

    0

相关资讯

CSE 2016掠影:从指南到实践,全面加强糖尿病管理

由中华医学会内分泌学分会主办的第十五次全国内分泌学学术会议(CSE 2016)近期在北京召开。本次会议内容丰富,专题报告和讨论、病例讨论、演讲比赛等各种学术内容精彩纷呈,我们精选了9月1日一场关于二肽基肽酶4(DPP-4)抑制剂“从过去到未来”的内容与您分享。从指南到临床看DPP-4抑制剂的疗效及安全性陈璐璐教授华中科技大学同济医学院附属协和医院陈璐璐教授从指南谈起,指出目前DPP-4抑制剂在糖尿

Crit Care:放松危重糖尿病患者的血糖控制目标,不会增加酮症酸中毒风险

对危重糖尿病患者,放松血糖控制,是否会增加酮生产和酮症酸中毒?基于此,我们进行了研究,旨在评估放松危重糖尿病患者的血糖控制后,患者的酮症、酮尿和酮症酸中毒的发生情况。 本项前瞻性观察队列研究纳入了60例危重糖尿病患者,均来自澳大利亚某三级ICU病房。在ICU住院期间进行了血液和尿液中酮体检测。所有患者均不执行严格血糖控制,反而将血糖水平目标值(BGL)定在10-14mmol/l之间。入住IC

EASD 2016:闵科夫斯基奖:线粒体和能量转换对2型糖尿病的抵抗作用

会议快讯:闵科夫斯基奖(Minkowski Prize)旨在表彰对糖尿病的相关研究及进展具有突出贡献的欧洲学者。第52届欧洲糖尿病研究协会(EASD)年会上,来自荷兰马斯特里赫特大学医学中心营养与转化学院的Patrick Schrauwen教授斩获第51届Minkowski奖,并在慕尼黑当地时间9月15日下午发表了题为“线粒体和能量转换对2型糖尿病的抵抗作用(Let's energise: mit

Diabetes Care:抑郁症让糖尿病患者的慢性肾脏疾病风险增加?

背景:伴抑郁症的糖尿病患者,其慢性肾脏疾病(CKD)风险是否会增加?我们对美国糖尿病退伍军人进行了研究,探究抑郁症和CKD发生率、心血管事件发生率和死亡率之间的联系。 方法:本项全国性前瞻性队列研究从超过300万美国退伍军人(基线估计肾小球滤过率(eGFR)≥60 mL/min/1.73 m2)中识别了933211例糖尿病患者。根据ICD-9-CM编码诊断糖尿病,HbA1c >6.4%

Diabetes Care:复发性糖尿病酮症酸中毒、医疗服务分化和死亡率研究

背景:一部分糖尿病患者会因为糖尿病酮症酸中毒(DKA)反复住院治疗,称为复发性DKA,常常会导致患者更差的预后。本研究在芝加哥地区的六所机构里进行,对复发性DKA、医疗服务分化和死亡率等情况进行了评估。 方法:通过HealthLNK识别了2006-2012年间的3615名DKA(ICD-9 250.1x)患者,因为DKA共住院5591次。获取了患者的人口和临床数据。DKA发作超过一次,定义为

Diabetes Care:2型糖尿病患者出现微血管病变,周围动脉疾病风险高!

目的:动脉帮助输送富含氧和各种营养物质的血液到身体的各部位。当下肢动脉阻塞后,就无法获得足够的血液或氧气,这时称其为周围动脉疾病(PAD)。 PAD是2型糖尿病患者发生动脉粥样硬化的常见表现,但是其他血管疾病和PAD之间联系的相关研究十分的少。我们对2型糖尿病患者进行了研究,探究既往微血管和大血管病变对主要PAD风险的影响。 方法:研究纳入了10624例2型糖尿病患者,基线没有主要PA